Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease

被引：11

作者：

Herth, Felix J. F. ^{[1
,2
]}

Bramlage, Peter ^{[3
]}

Mueller-Wieland, Dirk ^{[4
]}

机构：

[1] Heidelberg Univ, Thoraxklin, Dept Pneumol & Crit Care Med, DE-69126 Heidelberg, Germany

[2] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany

[3] Inst Pharmacol & Prevent Med, Mahlow, Germany

[4] Asklepios Klin St Georg, Dept Internal Med Endocrinol Diabet & Metab, Hamburg, Germany

来源：

RESPIRATION | 2015年 / 89卷 / 01期

关键词：

Chronic obstructive pulmonary disease; Diabetes; Hyperglycemia; Inhaled corticosteroids; FLUTICASONE PROPIONATE/SALMETEROL 250/50; METERED-DOSE INHALER; COPD PATIENTS; SALMETEROL/FLUTICASONE PROPIONATE; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; MU-G; EXACERBATIONS; BUDESONIDE; EFFICACY;

D O I：

10.1159/000368371

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Recent studies have suggested that inhaled corticosteroids (ICS) play a role in the development of hyperglycemia and type-2 diabetes in patients with chronic obstructive pulmonary disease (COPD). Nevertheless, this corticosteroid-associated adverse effect remains controversial. Moreover, the pharmacokinetic properties and patient characteristics that might contribute to an increased risk for diabetes upon ICS exposure have not been thoroughly investigated. In the present review, we critically discuss current evidence regarding the relationship between ICS therapy in COPD patients and an increased risk for the incidence and progression of type-2 diabetes. In addition, we address therapeutic conditions, clinical implications, and future perspectives related to this potentially important ICS-associated adverse effect in COPD patients. (C) 2014 S. Karger AG, Basel

引用

页码：66 / 75

页数：10

共 69 条

[1] Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate [J].

Allen, Ann ;

Bareille, Philippe J. ;

Rousell, Vicki M. .

CLINICAL PHARMACOKINETICS, 2013, 52 (01) :37-42

[2]

Altose MD, 2000, NEW ENGL J MED, V343, P1902

[3]

Antón E, 2013, EXPERT REV RESP MED, V7, P25, DOI [10.1586/ers.13.14, 10.1586/ERS.13.14]

[4] Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes [J].

Anzueto, Antonio ;

Ferguson, Gary T. ;

Feldman, Greg ;

Chinsky, Kenneth ;

Seibert, Allan ;

Emmett, Amanda ;

Knobil, Katharine ;

O'Dell, Dianne ;

Kalberg, Christopher ;

Crater, Glenn .

COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2009, 6 (05) :320-329

[5] Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly [J].

Blackburn, D ;

Hux, J ;

Mamdani, M .

JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (09) :717-720

[6] Continuous Monitoring of Circadian Glycemic Patterns in Patients Receiving Prednisolone for COPD [J].

Burt, Morton G. ;

Roberts, Gregory W. ;

Aguilar-Loza, Norma R. ;

Frith, Peter ;

Stranks, Stephen N. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) :1789-1796

[7] Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].

Calverley, P ;

Pauwels, R ;

Vestbo, J ;

Jones, P ;

Pride, N ;

Gulsvik, A ;

Anderson, J ;

Maden, C .

LANCET, 2003, 361 (9356) :449-456

[8] Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].

Calverley, Peter M. A. ;

Anderson, Julie A. ;

Celli, Bartolome ;

Ferguson, Gary T. ;

Jenkins, Christine ;

Jones, Paul W. ;

Yates, Julie C. ;

Vestbo, Jorgen ;

Calverley, P. M. A. ;

Anderson, J. A. ;

Celli, B. ;

Ferguson, G. T. ;

Jenkins, C. ;

Jones, P. W. ;

Knobil, K. ;

Yates, J. C. ;

Vestbo, J. ;

Cherniack, R. ;

Similowski, T. ;

Cleland, J. ;

Whitehead, A. ;

Wise, R. ;

McGarvey, L. ;

John, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789

[9] Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol [J].

Calverley, Peter M. A. ;

Martinez, Fernando J. ;

Fabbri, Leonardo M. ;

Goehring, Udo-Michael ;

Rabe, Klaus F. .

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 :375-382

[10] Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [J].

Calverley, PM ;

Boonsawat, W ;

Cseke, Z ;

Zhong, N ;

Peterson, S ;

Olsson, H .

EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) :912-919

← 1 2 3 4 5 6 7 →